Video

Evolving Standard of Care for Patients Diagnosed with Ph+ ALL

Author(s):

Amanda Przespolewski, DO,Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer Center

Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Related Videos
    Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
    Ongoing Research to Watch in Ovarian Cancer
    Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
    Additional Potential Roles for Mirvatuximab Soravtansine and Other ADCs in Ovarian Cancer
    Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
    PICCOLO Data for Mirvatuximab Soravtansine in FRα+, Platinum-Sensitive Ovarian Cancer
    Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
    Testing for FRα in Ovarian Cancer
    Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
    How Mirvatuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer
    Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
    Current Treatment Considerations for Platinum-Resistant Ovarian Cancer
    Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
    Other Key Follicular Lymphoma Data From ASH 2024
    Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
    Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma
    Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
    2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma
    Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.
    CD19 Expression Loss and Tafasitamab in R/R DLBCL
    Related Content